Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) released its Monthly Return for Equity Issuer for the period ended 30 September 2026, detailing sizeable H-share repurchases and confirming compliance with Hong Kong’s public-float requirements.

Key Takeaways

1. Share Capital Structure • Authorised / registered share capital remained unchanged at 2.67 billion shares (par value: RMB 1 per share). • Issued shares (excluding treasury) totalled 2.63 billion, comprising: – 2.10 billion A shares (no monthly change). – 529.61 million H shares, down by 11.08 million month-on-month following repurchases.

2. Accelerated H-Share Buy-backs • Between 1–25 September 2026 the company repurchased 11.08 million H shares on the Hong Kong Stock Exchange. • Purchase prices ranged from HK$16.21 to HK$18.16 per share, for an aggregate consideration of approximately HK$189.36 million. • All repurchased shares were retained as treasury stock, increasing the H-share treasury balance to 22.33 million shares (4.04 % of total H shares).

3. Treasury Position and Public Float • Total treasury shares stood at 42.24 million (1.58 % of total share capital) at month-end. • Despite the additional buy-backs, Fosun Pharma affirmed that the free-float of its H shares exceeds the 5 % minimum required under Hong Kong Listing Rule 19A.28B.

4. Equity Incentive Schemes • A-share options: 5.17 million options remained outstanding under the 2025 A-Share Option Scheme after 1,800 options lapsed in September; no new shares were issued. • H-share RSUs: 4,200 RSUs lapsed during the month, leaving 12.07 million RSUs outstanding under the 2025 H-Share RSU Scheme.

Implications

The September repurchases reduce Fosun Pharma’s free-float H-share base by roughly 2.0 %, signalling ongoing capital management efforts authorised at the 16 June 2026 general meeting. The stable authorised capital and unchanged A-share count suggest the company’s current focus is on optimising its H-share structure rather than broad equity expansion. With ample headroom above the 5 % public-float threshold and a growing treasury stock, Fosun Pharma retains flexibility for future share incentive settlements or potential cancellation strategies.